PharmaTher Holdings Past Earnings Performance
Past criteria checks 0/6
PharmaTher Holdings's earnings have been declining at an average annual rate of -40.8%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.
Key information
-40.8%
Earnings growth rate
-45.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | -110.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How PharmaTher Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 0 | -2 | 1 | 1 |
| 31 May 24 | 0 | -3 | 1 | 2 |
| 29 Feb 24 | 0 | -4 | 1 | 3 |
| 30 Nov 23 | 0 | -5 | 1 | 3 |
| 31 Aug 23 | 0 | -6 | 1 | 3 |
| 31 May 23 | 0 | -6 | 1 | 3 |
| 28 Feb 23 | 0 | -5 | 1 | 3 |
| 30 Nov 22 | 0 | -7 | 1 | 3 |
| 31 Aug 22 | 0 | -5 | 1 | 3 |
| 31 May 22 | 0 | -4 | 1 | 3 |
| 28 Feb 22 | 0 | -4 | 1 | 2 |
| 30 Nov 21 | 0 | 4 | 1 | 1 |
| 31 Aug 21 | 0 | 3 | 1 | 1 |
| 31 May 21 | 0 | 3 | 2 | 1 |
Quality Earnings: PHRM is currently unprofitable.
Growing Profit Margin: PHRM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHRM is unprofitable, and losses have increased over the past 5 years at a rate of 40.8% per year.
Accelerating Growth: Unable to compare PHRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHRM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: PHRM has a negative Return on Equity (-110.51%), as it is currently unprofitable.